phentermine Lomaira 8 mg
Selected indexed studies
- Obesity Management in Adults: A Review. (JAMA, 2023) [PMID:38015216]
- Medications for Obesity: A Review. (JAMA, 2024) [PMID:39037780]
- Obesity in Adolescents: A Review. (JAMA, 2024) [PMID:39102244]
_Worker-drafted node — pending editorial review._
Connections
phentermine Lomaira 8 mg is a side effect of
Sources
- Obesity Management in Adults: A Review. (2023) pubmed
- Medications for Obesity: A Review. (2024) pubmed
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. (2024) pubmed
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. (2016) pubmed
- Obesity in Adolescents: A Review. (2024) pubmed
- Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. (2019) pubmed
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. (2011) pubmed
- Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) pubmed
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. (2022) pubmed
- Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. (2025) pubmed